BR0312149A - Métodos para lisar um coágulo sanguìneo, para degradar proteoliticamente um coágulo sanguìneo, para restaurar a desobstrução em um dispositivo de acesso vascular permanente e para restaurar a função a um dispositico de acesso vascular permanente, e, uso de uma metaloproteinase fibrinolìtica - Google Patents

Métodos para lisar um coágulo sanguìneo, para degradar proteoliticamente um coágulo sanguìneo, para restaurar a desobstrução em um dispositivo de acesso vascular permanente e para restaurar a função a um dispositico de acesso vascular permanente, e, uso de uma metaloproteinase fibrinolìtica

Info

Publication number
BR0312149A
BR0312149A BR0312149-6A BR0312149A BR0312149A BR 0312149 A BR0312149 A BR 0312149A BR 0312149 A BR0312149 A BR 0312149A BR 0312149 A BR0312149 A BR 0312149A
Authority
BR
Brazil
Prior art keywords
vascular access
access device
blood clot
restoring
permanent vascular
Prior art date
Application number
BR0312149-6A
Other languages
English (en)
Inventor
Christopher F Toombs
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR0312149A publication Critical patent/BR0312149A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04—Macromolecular materials
    • A61L29/044—Proteins; Polypeptides; Degradation products thereof
    • A61L29/048—Other specific proteins or polypeptides not covered by A61L29/045 - A61L29/047
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

"MéTODOS PARA LISAR UM COáGULO SANGUìNEO, PARA DEGRADAR PROTEOLITICAMENTE UM COáGULO SANGuìNEO, PARA RESTAURAR A DESOBSTRUçãO EM UM DISPOSITIVO DE ACESSO VASCULAR PERMANENTE E PARA RESTAURAR A FUNçãO A UM DISPOSITIVO DE ACESSO VASCULAR PERMANENTE, E, USO DE UMA METALOPROTEINASE FIBRINOLìTICA". Um método é fornecido para a administração intravascular localizada de uma metaloproteinase fibrinolítica a um paciente humano em quantidades que sejam seguras e eficazes para lisar um coágulo sang³ineo contendo fibrina oclusora, enquanto também evita os efeitos neutralizantes da macroglobulina <244>~ 2~ no sangue circulante. Um método é também fornecido para o tratamento de um coágulo sang³íneo em torno ou ligado a um dispositivo de acesso vascular permanente. Um método para restaurar a desobstrução e função de um dispositivo de acesso vascular permanente também é fornecido.
BR0312149-6A 2002-06-21 2003-06-23 Métodos para lisar um coágulo sanguìneo, para degradar proteoliticamente um coágulo sanguìneo, para restaurar a desobstrução em um dispositivo de acesso vascular permanente e para restaurar a função a um dispositico de acesso vascular permanente, e, uso de uma metaloproteinase fibrinolìtica BR0312149A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/177,916 US7033776B2 (en) 1999-12-17 2002-06-21 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
PCT/US2003/019702 WO2004000348A1 (en) 2002-06-21 2003-06-23 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases

Publications (1)

Publication Number Publication Date
BR0312149A true BR0312149A (pt) 2005-03-29

Family

ID=29999111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312149-6A BR0312149A (pt) 2002-06-21 2003-06-23 Métodos para lisar um coágulo sanguìneo, para degradar proteoliticamente um coágulo sanguìneo, para restaurar a desobstrução em um dispositivo de acesso vascular permanente e para restaurar a função a um dispositico de acesso vascular permanente, e, uso de uma metaloproteinase fibrinolìtica

Country Status (17)

Country Link
US (4) US7033776B2 (pt)
EP (1) EP1531856A4 (pt)
JP (1) JP2005530846A (pt)
KR (1) KR20050047506A (pt)
CN (1) CN1674928A (pt)
AU (1) AU2003279258A1 (pt)
BR (1) BR0312149A (pt)
CA (1) CA2489997A1 (pt)
CZ (1) CZ200523A3 (pt)
IL (1) IL165834A0 (pt)
MX (1) MXPA04012847A (pt)
NO (1) NO20050328L (pt)
NZ (1) NZ537454A (pt)
PL (1) PL377634A1 (pt)
SK (1) SK50032005A3 (pt)
WO (1) WO2004000348A1 (pt)
ZA (1) ZA200500610B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586023B2 (en) 1998-02-06 2017-03-07 Boston Scientific Limited Direct stream hydrodynamic catheter system
WO2009117663A2 (en) * 2008-03-20 2009-09-24 Medrad, Inc. Direct stream hydrodynamic catheter system
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US20080275393A1 (en) * 2004-08-24 2008-11-06 Bonnette Michael J Isolation thrombectomy catheter system
US8162878B2 (en) 2005-12-05 2012-04-24 Medrad, Inc. Exhaust-pressure-operated balloon catheter system
EP1986568B1 (en) 2006-02-03 2017-04-05 Covidien LP Methods and devices for restoring blood flow within blocked vasculature
US8303538B2 (en) 2007-12-17 2012-11-06 Medrad, Inc. Rheolytic thrombectomy catheter with self-inflating distal balloon
US9717896B2 (en) * 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
EP2227285A4 (en) * 2007-12-26 2013-07-31 Medrad Inc RHEOMYTIC THROMBECTOMY CATHETER WITH SELF-CONTAINING PROXIMAL BALLOON HAVING INFUSION CAPACITY OF MEDICAMENT
EP2403583B1 (en) 2009-03-06 2016-10-19 Lazarus Effect, Inc. Retrieval systems
EP2512576B1 (en) * 2009-12-14 2016-05-25 Michael G. Tal Intravascular catheter with positioning markers
CN107206207B (zh) * 2015-01-09 2021-04-27 阿克瑞特医学治疗有限公司 栓塞微导管
US10456560B2 (en) 2015-02-11 2019-10-29 Covidien Lp Expandable tip medical devices and methods
WO2016139590A1 (en) 2015-03-02 2016-09-09 Accurate Medical Therapeutics Ltd. Embolization particulates for occluding a blood vessel
CN105561463A (zh) * 2015-12-17 2016-05-11 邓朝胜 一种Swan-Ganz漂浮导管引导鞘管导入选择性目标器官的方法
ES2865433T3 (es) 2016-05-04 2021-10-15 Accurate Medical Therapeutics Ltd Cabezal de microcatéter de embolización que tiene un patrón ranurado
RU2662145C2 (ru) * 2017-01-23 2018-07-23 Ильдар Наилевич Нурмеев Способ профилактики тромбоза у пациентов с центральным венозным катетером
CN107233342A (zh) * 2017-06-12 2017-10-10 揭阳市润达肠衣有限公司 一种含甲氧苄啶的固体分散体及其制备方法
WO2019087191A1 (en) 2017-11-02 2019-05-09 Accurate Medical Therapeutics Ltd. Embolization catheter with integral filter
EP3972500B1 (en) 2019-05-23 2025-04-30 Accurate Medical Therapeutics Ltd. Embolization catheter for reflux free delivery of microspheres
US20210121675A1 (en) * 2019-10-29 2021-04-29 Bard Access Systems, Inc. Systems, Devices, and Methods For Thrombolysis
CN111141902A (zh) * 2020-01-21 2020-05-12 佘钊炜 凝血检测装置

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81685A (en) * 1868-09-01 Improvement in harvester-rakes
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
DE69133066T2 (de) 1990-01-16 2003-03-06 Centro De Ingenieria Genetica Y Biotecnologia, Cubanacan Playa Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsverfahren und transformierte Mikroorganismen
US5709676A (en) 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
JP3537440B2 (ja) 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
FR2730579B1 (fr) 1995-02-10 1997-05-09 2B Technology Sarl Appareil portatif destine a l'exercice de diction de stimuli vocaux
GB9504657D0 (en) 1995-03-08 1995-04-26 Neil Michael J O An improved artificial airway device
US5626564A (en) 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US20020081685A1 (en) 2000-08-03 2002-06-27 Fox Brian A. Disintegrin homologs, ZSNK10, ZSNK11, and ZSNK12
US20050085769A1 (en) * 2001-07-17 2005-04-21 Kerberos Proximal Solutions Fluid exchange system for controlled and localized irrigation and aspiration
US20060095121A1 (en) * 2004-10-28 2006-05-04 Medtronic Vascular, Inc. Autologous platelet gel on a stent graft

Also Published As

Publication number Publication date
US7033776B2 (en) 2006-04-25
US7314728B2 (en) 2008-01-01
US20060035299A1 (en) 2006-02-16
EP1531856A1 (en) 2005-05-25
US20060029592A1 (en) 2006-02-09
WO2004000348A1 (en) 2003-12-31
NZ537454A (en) 2008-05-30
US7316911B2 (en) 2008-01-08
CN1674928A (zh) 2005-09-28
CA2489997A1 (en) 2003-12-31
NO20050328L (no) 2005-03-17
SK50032005A3 (sk) 2005-12-01
US20020197246A1 (en) 2002-12-26
KR20050047506A (ko) 2005-05-20
EP1531856A4 (en) 2008-08-13
IL165834A0 (en) 2006-01-15
US20080095760A1 (en) 2008-04-24
MXPA04012847A (es) 2005-02-24
PL377634A1 (pl) 2006-02-06
AU2003279258A1 (en) 2004-01-06
ZA200500610B (en) 2005-09-28
CZ200523A3 (cs) 2005-09-14
JP2005530846A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
BR0312149A (pt) Métodos para lisar um coágulo sanguìneo, para degradar proteoliticamente um coágulo sanguìneo, para restaurar a desobstrução em um dispositivo de acesso vascular permanente e para restaurar a função a um dispositico de acesso vascular permanente, e, uso de uma metaloproteinase fibrinolìtica
Romiti et al. Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
PT880350E (pt) Tratamento de esclerose multipla
SE9702860D0 (sv) New use
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
BR9916398A (pt) Agente radiossensibilizador para o tratamento de tecido doente usando-se radiossensibilização ou radiação ionizante, e, método de tratamento de tecido doente
WO2002049501A3 (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
DK0969813T3 (da) Topisk farmaceutisk sammensætning omfattende et kolinergt middel eller et calciumkanalblokerende middel
WO2007089454A3 (en) Methods for enhancing skin treatments
WO2003020202A3 (en) Method for reducing hypertension and heart failure
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
DE69109292D1 (de) Verminderung oder verhütung der von arzneimitteln verursachten hautreizung.
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
BRPI0509420A (pt) método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
ID23441A (id) Komposisi yang mengandung fructan untuk pencegahan dan pengobatan kanker usus dan metode untuk pencegahan dan pengobatan kanker usus
EP0671414A4 (en) ANTITHROMBOTIC.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
Wollina Disorders caused by physical and chemical damage
BR9908713A (pt) Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A,9A E 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.